4DMedical Ltd (ASX: 4DX) Share Price and News
Price
$0.26
Movement
0.01 (-3.7%)
as at 1 Apr - Closed (20 mins delayed)
52 Week Range
$0.2675 - $0.715
1 Year Return
-60.0%
4DMedical Ltd Chart and Price Data
2025
2025
2025
2025
$0.25
$0.50
$0.75
$0.25
$0.50
$0.75
$0.25
$0.50
$0.75
$0.25
$0.50
$0.75
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$117.11 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
450.42 million
Earnings per share
-0.114
Dividend per share
N/A
Year To Date Return
-39.58%
Earnings Yield
N/A
Franking
-
Share Price
$0.26
Day Change
0.01 (-3.7%)
52 Week Range
$0.2675 - $0.715
Yesterday's Close
$0.27
Today's Open
$0.27
Days Range
$0.2525 - $0.27
Volume
1,617,934
Avg. Volume (1 month)
1,026,457
Turnover
$423,755
as at 1 Apr - Closed
4DMedical Ltd (ASX: 4DX)
Latest News
Healthcare Shares
Guess which ASX medical share has exploded 275% in a month?
Share Gainers
5 top ASX shares that would have more than doubled your money in 2023
Healthcare Shares
Guess which ASX healthcare share is rocketing 67% on a US hospital deal
Share Gainers
In a sea of red, these ASX All Ords shares are leaping higher on Monday
Share Gainers
Why is the 4DMedical share price rocketing 20% on Wednesday?
Earnings Results
Why has the 4D Medical share price popped 7% in a month?
Healthcare Shares
Why is the 4DMedical share price exploding 40% today?
Healthcare Shares
40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods
Share Gainers
Why is the 4DMedical (ASX:4DX) share price rocketing 30% today?
Healthcare Shares
4DMedical (ASX:4DX) share price launches 19% on first commercial scans
Healthcare Shares
4DMedical (ASX:4DX) share price gains amid boss' confidence for FY22
Share Market News
ASX 200 falls, Metcash down, 4DMedical drops
Frequently Asked Questions
-
No, 4DMedical does not pay dividends at this time.
-
4DMedical listed on the ASX on 7 August 2020.
4DX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 1st Apr 2025 2025-04-01T08:46:10 | Letter to Shareholders, Notice of EGM & Proxy Form | YesNo | 8:46am | 27 | 605k |
| 26th Mar 2025 2025-03-26T09:58:04 | Cost reduction program delivers $6.5m in annualised savings | YesNo | 9:58am | 3 | 200k |
| 25th Mar 2025 2025-03-25T17:34:30 | Target Market Determination | YesNo | 5:34pm | 9 | 163k |
| 25th Mar 2025 2025-03-25T17:31:45 | Prospectus | YesNo | 5:31pm | 45 | 436k |
| 25th Mar 2025 2025-03-25T10:57:08 | Application for quotation of securities - 4DX | YesNo | 10:57am | 7 | 17k |
| 25th Mar 2025 2025-03-25T09:30:53 | 4DMedical completes oversubscribed $8.4m SPP | YesNo | 9:30am | 3 | 215k |
| 11th Mar 2025 2025-03-11T08:24:31 | 3-year contract extension secured with the Cleveland Clinic | YesNo | 8:24am | 2 | 192k |
| 3rd Mar 2025 2025-03-03T15:08:16 | Notification of cessation of securities - 4DX | YesNo | 3:08pm | 5 | 14k |
| 3rd Mar 2025 2025-03-03T14:55:31 | Change of Director's Interest Notice | YesNo | 2:55pm | 3 | 269k |
| 3rd Mar 2025 2025-03-03T14:55:26 | Change of Director's Interest Notice | YesNo | 2:55pm | 4 | 387k |
About 4DMedical Ltd
4DMedical Ltd (ASX: 4DX) is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. It is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.
The technology uses existing imaging systems and allows X-ray images to be taken simultaneously from various angles. Using image-processing methods adapted from aerospace engineering, the motion of lung tissue can be measured. This allows ventilation to be calculated at each stage of the breath and at every location within the lung. These measurements are then visualized as a coloured heat map to help medical professionals accurately identify ventilation deficits.
The 4DMedical technology is patented in key jurisdictions, including the US and Australia. The company is aiming to secure a slice of the global lung imaging market. The US market alone was valued at more than $US30 billion in normal pre-COVID diagnostic conditions.
4DX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | $0.27 | $-0.02 | -6.90% | 1,746,176 | $0.29 | $0.29 | $0.27 |
| 28 Mar 2025 | $0.29 | $-0.03 | -9.52% | 2,050,460 | $0.32 | $0.32 | $0.29 |
| 27 Mar 2025 | $0.32 | $-0.01 | -3.13% | 1,148,787 | $0.32 | $0.32 | $0.32 |
| 26 Mar 2025 | $0.32 | $-0.04 | -11.27% | 2,593,834 | $0.35 | $0.35 | $0.32 |
| 25 Mar 2025 | $0.36 | $-0.01 | -2.78% | 1,129,206 | $0.36 | $0.37 | $0.35 |
| 24 Mar 2025 | $0.36 | $-0.02 | -5.33% | 771,570 | $0.37 | $0.38 | $0.36 |
| 21 Mar 2025 | $0.38 | $-0.01 | -2.63% | 116,874 | $0.39 | $0.39 | $0.38 |
| 20 Mar 2025 | $0.38 | $0.00 | 0.00% | 92,664 | $0.38 | $0.38 | $0.38 |
| 19 Mar 2025 | $0.38 | $0.01 | 2.70% | 306,052 | $0.37 | $0.38 | $0.37 |
| 18 Mar 2025 | $0.37 | $0.01 | 2.74% | 432,840 | $0.37 | $0.38 | $0.37 |
| 17 Mar 2025 | $0.37 | $-0.01 | -2.70% | 627,813 | $0.37 | $0.37 | $0.36 |
| 14 Mar 2025 | $0.37 | $0.02 | 5.63% | 249,854 | $0.36 | $0.37 | $0.36 |
| 13 Mar 2025 | $0.36 | $-0.01 | -2.74% | 1,073,898 | $0.37 | $0.37 | $0.36 |
| 12 Mar 2025 | $0.37 | $-0.01 | -2.67% | 747,183 | $0.38 | $0.38 | $0.37 |
| 11 Mar 2025 | $0.38 | $-0.02 | -5.13% | 1,148,713 | $0.39 | $0.39 | $0.37 |
| 10 Mar 2025 | $0.39 | $0.02 | 5.41% | 1,268,278 | $0.37 | $0.40 | $0.37 |
| 07 Mar 2025 | $0.37 | $0.01 | 2.74% | 1,783,125 | $0.37 | $0.38 | $0.36 |
| 06 Mar 2025 | $0.37 | $-0.01 | -2.67% | 964,991 | $0.37 | $0.38 | $0.37 |
| 05 Mar 2025 | $0.38 | $-0.01 | -2.63% | 1,145,242 | $0.38 | $0.38 | $0.37 |
| 04 Mar 2025 | $0.38 | $-0.01 | -2.60% | 1,311,667 | $0.39 | $0.39 | $0.38 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 15 Jan 2025 | Lilian (Lil) Bianchi | Buy | 105,649 | $54,409 |
Exercise of options.
|
| 15 Jan 2025 | Lilian (Lil) Bianchi | Buy | 91,257 | $46,997 |
Exercise of options.
|
| 15 Jan 2025 | Lilian (Lil) Bianchi | Exercise | 196,906 | $101,406 |
Exercise of options.
|
| 15 Jan 2025 | John Livingston | Exercise | 60,147 | $30,975 |
Exercise of options.
|
| 15 Jan 2025 | John Livingston | Buy | 60,147 | $30,975 |
Exercise of options.
|
| 15 Jan 2025 | Julian Sutton | Exercise | 60,147 | $30,975 |
Exercise of options.
|
| 15 Jan 2025 | Julian Sutton | Buy | 60,147 | $30,975 |
Exercise of options.
|
| 14 Jan 2025 | Geraldine McGinty | Exercise | 137,787 | $71,649 |
Conversion of securities.
|
| 14 Jan 2025 | Geraldine McGinty | Buy | 137,787 | $71,649 |
Conversion of securities.
|
| 14 Jan 2025 | Robert Figlin | Buy | 60,147 | $31,276 |
Conversion of securities.
|
| 14 Jan 2025 | Robert Figlin | Exercise | 60,147 | $31,276 |
Conversion of securities.
|
| 21 Nov 2024 | John Livingston | Issued | 60,147 | $36,250 |
Director remuneration.
|
| 21 Nov 2024 | Geraldine McGinty | Issued | 137,787 | $72,500 |
Director remuneration. VWAP, 137,787 Restricted Stock Units
|
| 21 Nov 2024 | Andreas Fouras | Issued | 775,339 | $348,902 |
Issue of options.
|
| 21 Nov 2024 | Julian Sutton | Issued | 60,147 | $36,250 |
Director remuneration.
|
| 21 Nov 2024 | Robert Figlin | Issued | 60,147 | $36,250 |
Issue of securities. vwap, 60,147 Restricted Stock Units
|
| 21 Nov 2024 | Lilian (Lil) Bianchi | Issued | 196,906 | $104,327 |
Director remuneration.
|
| 07 Aug 2024 | Andreas Fouras | Expiry | 914,000 | $411,300 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Andrew Livingston | Executive Director | Mar 2018 |
Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where John was Chief Executive Officer and Managing Director.
|
| Dr Robert Alan Figlin | Non-Executive Director | Dec 2016 |
Dr Figlin held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Robert serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He is Chair of the Medical Advisory Committee.
|
| Dr Andreas Fouras | Chief Executive OfficerManaging Director | Dec 2012 |
Dr Fouras career in academic research has a foundation gained within studying experimental fluid dynamics in the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. This research into wind tunnel quantification garnered recognition as a young leader in the scientific discipline of fluid dynamics, developing a number of new approaches to the imaging of gas and liquid flow. He is member of the Medical Advisory Committee.
|
| Ms Lilian (Lil) Bianchi | Non-Executive DirectorNon-Executive Chairman | Dec 2019 |
Ms Bianchi is an experienced Non-Executive Director with a focus on innovative companies operating in highly regulated environments including health, finance and infrastructure. She is Chair of the Risk Committee.
|
| Mr Julian Bernard Kingsley Sutton | Non-Executive Director | Sep 2017 |
Mr Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later worked for Towers Perrin in Brussels and London as an asset consultant before moving to Credit Suisse Asset Management and then Schroders Investment Management as a portfolio manager in their respective multi-manager teams. He is member of Risk Committee.
|
| Dr Geraldine Bernadette McGinty | Non-Executive Director | Sep 2023 |
Dr McGinty is an expert in health care strategy and imaging economics, and prominent advocate for patient-centred care. A Professor of Clinical Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs. He is member of the Medical Advisory Committee.
|
| Mr Hamish George | Company Secretary | Mar 2025 |
-
|
| Matt Tucker | Chief Commercial Officer |
-
|
|
| Simon Glover | Chief Financial Officer |
-
|
|
| Hamish George | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Velocimetry Consulting Pty Ltd | 64,838,000 | 15.79% |
| Citicorp Nominees Pty Limited | 23,268,218 | 5.67% |
| BNP Paribas Nominees Pty Ltd | 19,897,389 | 4.85% |
| HSBC Custody Nominees (Australia) Limited | 14,435,511 | 3.52% |
| Ryder Innovation Fund LP | 4,551,274 | 1.11% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,179,399 | 1.02% |
| Merrill Lynch (Australia) Nominees Pty Limited | 3,573,454 | 0.87% |
| Mr Damen Diamantopoulos | 3,090,000 | 0.75% |
| JP Morgan Nominees Australia Pty Limited | 2,806,425 | 0.68% |
| Alex Petrou & Christine Petrou | 2,484,471 | 0.61% |
| Mr Paul Tomlin | 2,416,870 | 0.59% |
| BNP Paribas Noms Pty Ltd | 2,101,511 | 0.51% |
| Pacific Custodians Pty Limited | 2,040,978 | 0.50% |
| Mrs Irene Wai-Ping Lee & Miss Yvonne Lee & Mr Wilson Lee | 1,997,346 | 0.49% |
| Sprout Group Pty Ltd | 1,769,331 | 0.43% |
| BNP Paribas Nominees Pty Ltd i | 1,737,816 | 0.42% |
| Mr Dev Jayram | 1,580,583 | 0.39% |
| Fang Family Investments Pty Ltd | 1,517,437 | 0.37% |
| Endless Smiles Pty Ltd | 1,500,000 | 0.37% |
| Wal Assets Pty Ltd | 1,411,487 | 0.34% |